Sökning: WFRF:(Maenpaa Johanna)
> (2016) >
The use of granuloc...
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer-Further observations from the IMPACT solid study
-
- Maenpaa, Johanna (författare)
- Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland.
-
- Varthalitis, Ioannis (författare)
- Chania Gen Hosp, Khania, Greece.
-
- Erdkamp, Frans (författare)
- Orbis Med Ctr, Sittard, Netherlands.
-
visa fler...
-
- Trojan, Andreas (författare)
- Brust Zentrum Zurich, Zurich, Switzerland.
-
- Krzemieniecki, Krzysztof (författare)
- Jagiellonian Univ, Oncol Clin, PL-31007 Krakow, Poland.
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Bendall, Kate (författare)
- Amgen Ltd, Uxbridge, Middx, England.
-
- Vogl, Florian D. (författare)
- Amgen Inc, Thousand Oaks, CA 91320 USA.
-
- Verma, Shailendra (författare)
- Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada.
-
visa färre...
-
Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland Chania Gen Hosp, Khania, Greece. (creator_code:org_t)
- Elsevier BV, 2016
- 2016
- Engelska.
-
Ingår i: Breast. - : Elsevier BV. - 0960-9776 .- 1532-3080. ; 25, s. 27-33
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To investigate the use and impact of granulocyte colony-stimulating factors (G-CSF) on chemotherapy delivery and neutropenia management in breast cancer in a clinical practice setting. Methods: IMPACT Solid was an international, prospective observational study in patients with a physician-assessed febrile neutropenia (FN) risk of >= 20%. This analysis focused on stages I-III breast cancer patients who received a standard chemotherapy regimen for which the FN risk was published. Chemotherapy delivery and neutropenia-related outcomes were reported according to the FN risk of the regimen and intent of G-CSF use. Results: 690 patients received a standard chemotherapy regimen; 483 received the textbook dose/schedule with a majority of these regimens (84%) having a FN risk >= 10%. Patients receiving a regimen with a FN risk >= 10% were younger with better performance status than those receiving a regimen with a FN risk < 10%. Patients who received higher-risk regimens were more likely to receive G-CSF primary prophylaxis (48% vs 22%), complete their planned chemotherapy (97% vs 88%) and achieve relative dose intensity >= 85% (93% vs 86%) than those receiving lower-risk regimens. Most first FN events (56%) occurred in cycles not supported with G-CSF primary prophylaxis. Conclusion: Physicians generally recommend standard adjuvant chemotherapy regimens and were more likely to follow G-CSF guidelines for younger, good performance status patients in the curative setting, and often modify standard regimens in more compromised patients. However, G-CSF support is not optimal, indicated by G-CSF primary prophylaxis use in < 50% of high-risk patients and observation of FN without G-CSF support.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Granulocyte colony-stimulating factor
- Neutropenia
- Chemotherapy delivery
- Clinical practice
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Breast
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas